Results 141 to 150 of about 657,615 (203)

Studies on poly (adenosine diphosphate ribose). V. Mechanism of hydrolysis of poly (adenosine diphosphate ribose) by snake venom phosphodiesterase.

The Journal of biological chemistry, 1970
H, Matsubara, S, Hasegawa, S, Fujimura, T, Shima, T, Sugimura   +4 more
openaire   +1 more source

Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats. [PDF]

Respir Res, 2013
Si MK, Mitaka C, Tulafu M, Abe S, Kitagawa M, Ikeda S, Eishi Y, Kurata S, Tomita M.   +8 more
europepmc   +1 more source

Abiotic synthesis of RNase-resistant phosphodiester and pyrophosphate-linked polymers via thermodynamically controlled wet-dry cycling. [PDF]

Sci Rep
Simonis P, Rheinstädter HV, Masevičius V, Pudritz RE, Bujold KE, Rheinstädter MC.   +5 more
europepmc   +1 more source

Comment on "<i>PARP-1</i> rs1136410 Polymorphism and Gastrointestinal Cancer Risk: A Meta-Analysis of Cancer-Type and Ethnic-Specific Associations". [PDF]

Medeni Med J
Alkan O, Nazli I, Basgoze A.
europepmc   +1 more source

Poly(ADP-ribose) (PAR) exhibits ion-dependent structural properties distinct from RNA. [PDF]

Nucleic Acids Res
Baidya L, Zhang H, Nguyen HT.
europepmc   +1 more source

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer. [PDF]

J Ovarian Res
Ye L, Chen Y, Chen Y, Zhao Q, Cheng X, Wang X, Xu X, Guo W, Chen X, Ni J.   +9 more
europepmc   +1 more source

Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by <i>BRCA</i> status: a retrospective cohort study. [PDF]

ESMO Real World Data Digit Oncol
Zucker K, Pickwell-Smith B, Samani A, Sujenthiran A, Pittell H, Mpofu P, Hall G.   +6 more
europepmc   +1 more source

Interactomics of SARS-CoV-2 Macrodomain 1 Reveals Putative Clients of ADP-Ribosyl Hydrolase Activity. [PDF]

Viruses
Cameron CD, Heilmann G, Roman BK, Plate L.   +3 more
europepmc   +1 more source

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP).   +63 more
europepmc   +1 more source